Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemiaMaxim Norkin, John R. Wingard, Nosha Farhadfar et al.|Blood Cancer Journal|2017Cited by 26
A new model to predict remission status in AML patients based on day 14 bone marrow biopsyMaxim Norkin, Christopher R. Cogle, Myron Chang et al.|Leukemia Research|2016Cited by 14
Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone MarrowsMaxim Norkin, John R. Wingard, Jan S. Moreb et al.|Blood|2013Cited by 0
A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) BiopsyMaxim Norkin, Christopher R. Cogle, Myron Chang et al.|Blood|2015Cited by 0
Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) OutcomesLakshmikanth Katragadda, John R. Wingard, Maxim Norkin et al.|Blood|2015Cited by 0